http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Cardiorenal Protection in Diabetic Kidney Disease
Jason F. Lee,Ecaterina Berzan,Vikas S. Sridhar,Ayodele Odutayo,David Z.I. Cherney 대한내분비학회 2021 Endocrinology and metabolism Vol.36 No.2
Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent additionof data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk ofdiabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medicationsfor the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronickidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.